Gene Therapy For Hemophilia B
Brahm Goldstein, MD, Vice President, R&D, Hematology at CSL Behring, discusses HEMGENIX, a pivotal gene therapy for hemophilia B.
Brahm Goldstein, MD, Vice President, R&D, Hematology at CSL Behring, discusses HEMGENIX, a pivotal gene therapy for hemophilia B.
Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) are conducting a range of clinical trials of promising new treatments for patients with non-muscle invasive bladder…
Researchers have uncovered novel genetic variants associated with a higher risk of breast cancer–related mortality among women of African ancestry.
Enzalutamide with and without leuprolide improves rates of undetectable PSA levels compared with leuprolide alone in castration-sensitive prostate cancer.
In today’s episode, we bring you key highlights from ESMO Breast 2024, diving into important discussions surrounding the latest research…
Bladder Cancer statistics
CSPs increase thrombin generation in recipients but fail to show integrin activation.Procoagulant function of CSPs can be predicted by lyso-platelet activa
Findings from a phase 1b/2 study support the continued development of palazestrant plus ribociclib for patients with estrogen receptor-positive/HER2-negative metastatic breast cancer.
CD33/CD123 NANOBODY TCE kills single and double-positive cells, outperforming single-targeting TCE in a subset of AML samples.CD33/CD123-TCE efficiently ki
0:15 – Meeting Begins3:10 – Opening Keynote from Namandjé Bumpus, U.S. FDA and Peter Marks, CBER, U.S. FDA28:42 – The Evolution of Cell and Gene…